Recursion Pharmaceuticals

RXRXleader

Recursion uses biological foundation models and robotic cell biology to industrialize drug discovery, generating the world's largest searchable dataset of cellular phenomics.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($75M)

静态数据（加载实时财务…）

Partnership Revenue (80%)

Other (20%)

业务板块构成与主要客户

产品详情

Recursion OS (Drug Discovery Platform)20%

Biological foundation model trained on 50TB+ of cellular imaging data — screens millions of drug-disease combos at unprecedented speed.

Collaboration Revenue (Roche, Bayer)60%

Target discovery and hit identification partnerships with Roche and Bayer using the OS platform.

Internal Pipeline20%

15+ programs in oncology and neurological rare diseases derived from OS platform.

供应链关系

合作伙伴

NVIDIA Corporation

BioNeMo foundation model partnership

影响: strategic

roche

$150M target discovery collaboration

影响: critical

宏观与市场背景

헬스케어行业新闻

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

近期催化剂

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

AI 分析

点击「获取 AI 分析」以获得 Recursion Pharmaceuticals 的 AI 供应链分析。

企业信息

总部

Salt Lake City, Utah, USA

成立时间

2013

员工人数

1,800

官网

recursion.com

行业概况 — 헬스케어

行业新闻